10X GENOMICS INC's ticker is TXG and the CUSIP is 88025U109. A total of 328 filers reported holding 10X GENOMICS INC in Q3 2021. The put-call ratio across all filers is 2.03 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,885,503 | -35.4% | 94,194 | -12.6% | 0.01% | -25.0% |
| Q2 2023 | $6,016,146 | +6.1% | 107,739 | +6.0% | 0.01% | 0.0% |
| Q1 2023 | $5,670,049 | +50.9% | 101,632 | -1.4% | 0.01% | +33.3% |
| Q4 2022 | $3,757,802 | +20.7% | 103,123 | -5.7% | 0.01% | +20.0% |
| Q3 2022 | $3,113,000 | -37.8% | 109,300 | -1.2% | 0.01% | -37.5% |
| Q2 2022 | $5,007,000 | -50.7% | 110,645 | -17.2% | 0.01% | -38.5% |
| Q1 2022 | $10,164,000 | -51.7% | 133,618 | -5.4% | 0.01% | -48.0% |
| Q4 2021 | $21,030,000 | +4.1% | 141,178 | +1.7% | 0.02% | -3.8% |
| Q3 2021 | $20,202,000 | -31.5% | 138,766 | -7.9% | 0.03% | -29.7% |
| Q2 2021 | $29,496,000 | +49.0% | 150,630 | +37.7% | 0.04% | +42.3% |
| Q1 2021 | $19,799,000 | +28.0% | 109,389 | +0.2% | 0.03% | +18.2% |
| Q4 2020 | $15,466,000 | +22.5% | 109,225 | +7.8% | 0.02% | +10.0% |
| Q3 2020 | $12,630,000 | +51.0% | 101,302 | +8.1% | 0.02% | +33.3% |
| Q2 2020 | $8,366,000 | – | 93,670 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 1,358,528 | $49,504,760 | 100.00% |
| Meritech Capital Associates V L.L.C. | 1,061,682 | $38,687,692 | 9.44% |
| Decheng Capital Management III (Cayman), LLC | 359,554 | $13,102,148 | 4.90% |
| Sands Capital Ventures, LLC | 481,770 | $17,556 | 4.81% |
| Whitford Management LLC | 58,310 | $2,124,803 | 2.88% |
| FINANCIAL CONSULATE, INC | 156,457 | $5,701,293 | 1.99% |
| SRS Investment Management, LLC | 3,005,427 | $109,517,760 | 1.98% |
| BRANDYWINE MANAGERS, LLC | 11,208 | $408,420 | 1.43% |
| ARK Investment Management | 4,316,567 | $157,295,701 | 1.36% |
| Nikko Asset Management Americas, Inc. | 2,177,988 | $79,365,883 | 1.14% |